{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T13:05:46Z","timestamp":1792760746066,"version":"4.5.0"},"reference-count":30,"publisher":"Society of Nuclear Medicine","issue":"5","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["J Nucl Med"],"accepted":{"date-parts":[[2025,2,20]]},"published-print":{"date-parts":[[2025,5]]},"DOI":"10.2967\/jnumed.124.269299","type":"journal-article","created":{"date-parts":[[2025,3,13]],"date-time":"2025-03-13T12:20:28Z","timestamp":1741868428000},"page":"732-738","source":"Crossref","is-referenced-by-count":22,"title":["First-in-Human Phase 0 Study of AB001, a Prostate-Specific Membrane Antigen\u2013Targeted\n                    <sup>212<\/sup>\n                    Pb Radioligand, in Patients with Metastatic Castration-Resistant Prostate Cancer"],"prefix":"10.2967","volume":"66","author":[{"given":"Kjetil","family":"Berner","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eivor","family":"Hernes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Monika","family":"Kvassheim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mona-Elisabeth","family":"Revheim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julie","family":"Bastiansen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Silje","family":"Selboe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Charlotte L.","family":"Bakken","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Simen R.","family":"Gr\u00f8nnings\u00e6ter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"\u00d8yvind S.","family":"Bruland","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roy H.","family":"Larsen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lily","family":"Bouzelmat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vicki L.","family":"Jardine","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Caroline","family":"Stokke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1602","published-online":{"date-parts":[[2025,3,13]]},"reference":[{"key":"2025050105251687000_66.5.732.1","first-page":"227","article-title":"Prostate-specific membrane antigen-targeted theranostics: past, present, and future approaches","volume":"20","author":"Hawkey","year":"2022","journal-title":"Clin Adv Hematol Oncol."},{"key":"2025050105251687000_66.5.732.2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2107322"},{"key":"2025050105251687000_66.5.732.3","doi-asserted-by":"publisher","DOI":"10.1038\/s41573-020-0073-9"},{"key":"2025050105251687000_66.5.732.4","doi-asserted-by":"crossref","first-page":"1268","DOI":"10.1007\/s00259-024-06640-x","article-title":"EANM guidance document: dosimetry for first-in-human studies and early phase clinical trials","volume":"51","author":"Stokke","year":"2024","journal-title":"Eur J Nucl Med Mol Imaging."},{"key":"2025050105251687000_66.5.732.5","doi-asserted-by":"crossref","first-page":"880","DOI":"10.1038\/s41391-021-00349-w","article-title":"Evolving role of 225Ac-PSMA radioligand therapy in metastatic castration-resistant prostate cancer: a systematic review and meta-analysis","volume":"24","author":"Satapathy","year":"2021","journal-title":"Prostate Cancer Prostatic Dis."},{"key":"2025050105251687000_66.5.732.6","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1097\/RLU.0000000000002833","article-title":"Efficacy and safety of 177Lu-PSMA-617 radioligand therapy in metastatic castration-resistant prostate cancer patients","volume":"45","author":"Yadav","year":"2020","journal-title":"Clin Nucl Med."},{"key":"2025050105251687000_66.5.732.7","doi-asserted-by":"publisher","DOI":"10.1016\/j.eururo.2020.11.013"},{"key":"2025050105251687000_66.5.732.8","doi-asserted-by":"crossref","first-page":"580","DOI":"10.1002\/pros.24137","article-title":"225Ac-PSMA-617-targeted alpha therapy for the treatment of metastatic castration-resistant prostate cancer: a systematic review and meta-analysis","volume":"81","author":"Ballal","year":"2021","journal-title":"Prostate."},{"key":"2025050105251687000_66.5.732.9","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1007\/s00259-021-05434-9","article-title":"Global experience with PSMA-based alpha therapy in prostate cancer","volume":"49","author":"Sathekge","year":"2021","journal-title":"Eur J Nucl Med Mol Imaging."},{"key":"2025050105251687000_66.5.732.10","doi-asserted-by":"publisher","DOI":"10.2967\/jnumed.123.266774"},{"key":"2025050105251687000_66.5.732.11","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1002\/jlcr.3825","article-title":"Preparation of the alpha-emitting prostate-specific membrane antigen targeted radioligand [212Pb]Pb-NG001 for prostate cancer","volume":"63","author":"Stenberg","year":"2020","journal-title":"J Labelled Comp Radiopharm."},{"key":"2025050105251687000_66.5.732.12","doi-asserted-by":"crossref","unstructured":"Stenberg VY Larsen RH Ma LW . Evaluation of the PSMA-binding ligand 212Pb-NG001 in multicellular tumour spheroid and mouse models of prostate cancer. Int J Mol Sci. 2021;22:4815.","DOI":"10.3390\/ijms22094815"},{"key":"2025050105251687000_66.5.732.13","doi-asserted-by":"publisher","DOI":"10.2967\/jnumed.122.264455"},{"key":"2025050105251687000_66.5.732.14","doi-asserted-by":"crossref","unstructured":"Auranen K Mccutchan EA . Nuclear data sheets for A=212. NuDat 3.0 website. https:\/\/www.nndc.bnl.gov\/nudat\/. Published 2020. Accessed March 5, 2025.","DOI":"10.1016\/j.nds.2020.09.002"},{"key":"2025050105251687000_66.5.732.15","doi-asserted-by":"publisher","DOI":"10.1089\/cbr.2013.1531"},{"key":"2025050105251687000_66.5.732.16","doi-asserted-by":"crossref","first-page":"1490","DOI":"10.1007\/s00259-023-06529-1","article-title":"First-in-human SPECT\/CT imaging of [212Pb]Pb-VMT-alpha-NET in a patient with metastatic neuroendocrine tumor","volume":"51","author":"Michler","year":"2024","journal-title":"Eur J Nucl Med Mol Imaging."},{"key":"2025050105251687000_66.5.732.17","doi-asserted-by":"publisher","DOI":"10.2967\/jnumed.123.267189"},{"key":"2025050105251687000_66.5.732.18","doi-asserted-by":"publisher","DOI":"10.1097\/00000421-198212000-00014"},{"key":"2025050105251687000_66.5.732.19","doi-asserted-by":"publisher","DOI":"10.2967\/jnumed.122.264009"},{"key":"2025050105251687000_66.5.732.20","doi-asserted-by":"publisher","DOI":"10.1007\/s00259-016-3573-4"},{"key":"2025050105251687000_66.5.732.21","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1016\/S0021-9258(18)56468-1","article-title":"Measurement of specific gravities of whole blood and plasma by standard copper sulfate solutions","volume":"183","author":"Phillips","year":"1950","journal-title":"J Biol Chem."},{"key":"2025050105251687000_66.5.732.22","doi-asserted-by":"publisher","DOI":"10.2967\/jnumed.117.191395"},{"key":"2025050105251687000_66.5.732.23","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1186\/s40658-022-00481-z","article-title":"Quantitative SPECT\/CT imaging of lead-212: a phantom study","volume":"9","author":"Kvassheim","year":"2022","journal-title":"EJNMMI Phys."},{"key":"2025050105251687000_66.5.732.24","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1097\/00004032-200307000-00023","article-title":"ICRU report 67: absorbed-dose specification in nuclear medicine","volume":"85","author":"Kearfott","year":"2003","journal-title":"Health Phys."},{"key":"2025050105251687000_66.5.732.25","doi-asserted-by":"publisher","DOI":"10.1177\/0146645317717209"},{"key":"2025050105251687000_66.5.732.26","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1186\/s13550-018-0386-4","article-title":"External radiation exposure, excretion, and effective half-life in 177Lu-PSMA-targeted therapies","volume":"8","author":"Kurth","year":"2018","journal-title":"EJNMMI Res."},{"key":"2025050105251687000_66.5.732.27","doi-asserted-by":"crossref","unstructured":"Stokke C Kvassheim M Blakkisrud J . Radionuclides for targeted therapy: physical properties. Molecules. 2022;27:5429.","DOI":"10.3390\/molecules27175429"},{"key":"2025050105251687000_66.5.732.28","doi-asserted-by":"publisher","DOI":"10.2967\/jnumed.121.263230"},{"key":"2025050105251687000_66.5.732.29","doi-asserted-by":"crossref","first-page":"4020","DOI":"10.1200\/JCO.2024.42.16_suppl.4020","article-title":"Safety, tolerability and efficacy of 212Pb-DOTAMTATE as a targeted alpha therapy for subjects with unresectable or metastatic somatostatin receptor-expressing gastroenteropancreatic neuroendocrine tumors (SSTR+ GEP-NETs): a phase 2 study","volume":"42","author":"Strosberg","year":"2024","journal-title":"J Clin Oncol."},{"key":"2025050105251687000_66.5.732.30","doi-asserted-by":"publisher","DOI":"10.2967\/jnumed.121.262017"}],"container-title":["Journal of Nuclear Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.2967\/jnumed.124.269299","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,1]],"date-time":"2025-05-01T08:26:48Z","timestamp":1746088008000},"score":1,"resource":{"primary":{"URL":"http:\/\/jnm.snmjournals.org\/lookup\/doi\/10.2967\/jnumed.124.269299"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3,13]]},"references-count":30,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2025,5,1]]},"published-print":{"date-parts":[[2025,5]]}},"alternative-id":["10.2967\/jnumed.124.269299"],"URL":"https:\/\/doi.org\/10.2967\/jnumed.124.269299","relation":{},"ISSN":["0161-5505","2159-662X"],"issn-type":[{"value":"0161-5505","type":"print"},{"value":"2159-662X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,3,13]]}}}